If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

How will the Trump administration's cuts to HIV research impact the progress that's been made towards ending the epidemic in the U.S.?

HIV/AIDS : Welcome to Medscape HIV/AIDS, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles, and trending stories.

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...